Efficacy and Safety of Adding Concomitant Chemotherapy to First-Line EGFR-TKI Therapy in Advanced EGFR-Mutated NSCLC: A GRADE-Assessed Systematic Review and Meta-Analysis of Randomized Controlled Trials With Trial Sequential Analysis

The benefit of adding chemotherapy to first-line epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in advanced EGFR-mutated non-small-cell lung cancer (NSCLC) remains uncertain. We evaluated the efficacy and safety of EGFR-TKI plus chemotherapy versus EGFR-TKI monotherapy. PubMed, Embase, and the Cochrane Library were searched from inception to August 2026 for randomized controlled trials (RCTs) comparing first-line EGFR-TKI plus chemotherapy with EGFR-TKI monotherapy in adults with advanced EGFR-mutated NSCLC. Random-effects models were used to pool hazard ratios (HRs) and risk ratios (RRs) with 95% CIs. Subgroup, sensitivity, trial sequential analysis, and GRADE assessments were performed. Seven RCTs involving 2454 patients were included. Combination therapy significantly improved overall survival (HR: 0.64; 95% CI: 0.53-0.77) and progression-free survival (HR: 0.54; 95% CI: 0.45-0.64) compared with EGFR-TKI monotherapy. Objective response rate was also higher with combination therapy (RR: 1.14; 95% CI: 1.07-1.20). However, combination therapy substantially increased treatment-related toxicity, particularly grade ≥3 and hematologic adverse events. Sensitivity analyses supported the robustness of the primary efficacy findings. Subgroup analyses demonstrated consistent OS and PFS benefits across EGFR-TKI generations. Adding chemotherapy to first-line EGFR-TKI therapy improves survival and tumor response in advanced EGFR-mutated NSCLC but increases treatment-related toxicity. These findings support combination therapy while highlighting the need to balance clinical benefit against treatment burden.

Authors

Institutions

Publication Details

Journal
American Journal of Clinical Oncology
Published
2026-11-16
DOI
https://doi.org/10.1097/coc.0000000000001393
Primary Topic
Lung Cancer Treatments and Mutations
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Efficacy and Safety of Adding Concomitant Chemotherapy to First-Line EGFR-TKI Therapy in Advanced EGFR-Mutated NSCLC: A GRADE-Assessed Systematic Review and Meta-Analysis of Randomized Controlled Trials With Trial Sequential Analysis

Asad Ullah Nawaz, Hassaan Abid, Muhammad Maaz Amjad, Sohana Memon et al.
1 links
American Journal of Clinical Oncology
Lung Cancer Treatments and Mutations
article

Efficacy and Safety of Adding Concomitant Chemotherapy to First-Line EGFR-TKI Therapy in Advanced EGFR-Mutated NSCLC: A GRADE-Assessed Systematic Review and Meta-Analysis of Randomized Controlled Trials With Trial Sequential Analysis

Asad Ullah Nawaz, Hassaan Abid, Muhammad Maaz Amjad, Sohana Memon, Mariya Khan, Mansoor Khalid, Muhammad H. Khattak, Yusra Iqbal, Muhammad F.I. Khan
article en

Abstract

The benefit of adding chemotherapy to first-line epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in advanced EGFR-mutated non-small-cell lung cancer (NSCLC) remains uncertain. We evaluated the efficacy and safety of EGFR-TKI plus chemotherapy versus EGFR-TKI monotherapy. PubMed, Embase, and the Cochrane Library were searched from inception to August 2026 for randomized controlled trials (RCTs) comparing first-line EGFR-TKI plus chemotherapy with EGFR-TKI monotherapy in adults with advanced EGFR-mutated NSCLC. Random-effects models were used to pool hazard ratios (HRs) and risk ratios (RRs) with 95% CIs. Subgroup, sensitivity, trial sequential analysis, and GRADE assessments were performed. Seven RCTs involving 2454 patients were included. Combination therapy significantly improved overall survival (HR: 0.64; 95% CI: 0.53-0.77) and progression-free survival (HR: 0.54; 95% CI: 0.45-0.64) compared with EGFR-TKI monotherapy. Objective response rate was also higher with combination therapy (RR: 1.14; 95% CI: 1.07-1.20). However, combination therapy substantially increased treatment-related toxicity, particularly grade ≥3 and hematologic adverse events. Sensitivity analyses supported the robustness of the primary efficacy findings. Subgroup analyses demonstrated consistent OS and PFS benefits across EGFR-TKI generations. Adding chemotherapy to first-line EGFR-TKI therapy improves survival and tumor response in advanced EGFR-mutated NSCLC but increases treatment-related toxicity. These findings support combination therapy while highlighting the need to balance clinical benefit against treatment burden.

American Journal of Clinical Oncology
Liaquat University of Medical & Health Sciences (PK), Khyber Medical College (PK), Khyber Girls Medical College (PK), United Medical and Dental College (PK)
Good health and well-being
Lung Cancer Treatments and Mutations
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon